^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements

Published date:
02/24/2022
Excerpt:
...we report a 46-year-old female who was diagnosed with lung adenocarcinoma and identified carrying concurrent DCTN1-ALK and ALK-CLIP4 rearrangements by next generation sequencing (NGS) (638-gene panel). This patient showed partial response to crizotinib with a progress-free survival of 12 months
DOI:
https://doi.org/10.1111/1759-7714.14345